To address the continued rise of multi-drug-resistant microorganisms, the development of
novel drugs with new modes of action is urgently required. While humans biosynthesize the …

Malaria has been a major parasitic disease in tropical and subtropical regions and is
estimated to kill between one and two million people (mainly children) every year. Novel anti …

Fosmidomycin (FOS) is a naturally occurring compound active against the 1-deoxy-D-
xylulose 5-phosphate reductoisomerase (DXR) enzyme in the 2-C-methyl-D-erythritol 4 …

deoxy-d-xylulose 5-phosphate reductoisomerase (DXR) catalyzes the second step of the
non-mevalonate (or MEP) pathway that functions in several organisms and plants for the …

An efficient synthetic pathway to a series of novel “reverse” fosmidomycin analogues has
been developed, commencing from substituted benzylamines. In these analogues, the …

A six-step synthetic pathway has been established to access a series of racemic 2, 3-
dihydroxy-3-(N-substituted carbamoyl) propylphosphonic acid derivatives, designed to …

Herein a series of novel thiosemicarbazones (TSCs) derived from 2-oxoquinoline scaffold is
reported, and the target compounds have been successfully synthesized and characterized …

Abstract A series of N 2, N 2′-bis [4-hydroxycoumarin-3-yl) ethylidene]-2, 3-
dihydroxysuccino-hydrazides, containing 4-hydroxycoumarin, hydrazine and tartaric acid …

Unexpected substituent-dependent regioselectivty challenges in the synthesis of C-
benzylated (N-arylcarbamoyl) phosphonate esters have been resolved. The C-benzylated N …

Thia analogs of fosmidomycin are potent inhibitors of the non-mevalonate isoprenoid
biosynthesis enzyme 1-deoxy-d-xylulose 5-phosphate reductoisomerase (IspC, Dxr) of …